olezarsen sodium: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614	NDA	Ionis Pharmaceuticals, Inc.	71860-101-01	1 SYRINGE, GLASS in 1 CARTON (71860-101-01) / .8 mL in 1 SYRINGE, GLASS	2024-12-19
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

Olezarsen sodium, marketed under various brand names including Taurisolo and other formulations, is an emerging therapeutic agent primarily used for the management of lipid disorders, especially elevated triglyceride levels. As a chemically synthesized oligonucleotide therapy, it is designed to inhibit the expression of apolipoprotein C-III (apoC-III), a regulator involved in lipid metabolism. The increasing demand for effective treatments in hypertriglyceridemia and related cardiovascular conditions has intensified interest in Olezarsen sodium, establishing a complex global supply chain comprising raw material providers, contract manufacturing organizations (CMOs), and distributors. This article provides a comprehensive overview of suppliers involved in the production, formulation, and distribution of Olezarsen sodium, highlighting strategic sourcing, manufacturing capacity, regulatory compliance, and market dynamics.

Manufacturers of API (Active Pharmaceutical Ingredient): Olezarsen Sodium

1. IONIS Pharmaceuticals / Ionis Pharmaceuticals Inc.

Overview:
Ionis Pharmaceuticals is the pioneering biotech company that developed oligonucleotide-based therapies, including Olezarsen sodium. As the original innovator, Ionis actively involved in API development, early-stage manufacturing, and pipeline progression.

Supply Role:
Ionis specializes in the synthesis of oligonucleotide APIs, utilizing proprietary chemical synthesis platforms. The company provides the initial bulk API and may supply globally through strategic partnerships or licensing agreements.

Capacity & Compliance:
Ionis's manufacturing facilities in the United States comply with Good Manufacturing Practice (GMP) standards. Their capabilities extend to large-scale industrial synthesis necessary for commercial production.

Strategic Partnerships:
Ionis often partners with pharmaceutical companies to assist in manufacturing and distribution. For Olezarsen sodium, collaborations with large pharma entities like Novartis or BioPharma firms have been reported, facilitating wider access.

2. Novartis AG

Overview:
Novartis acquired rights to some oligonucleotide therapies through licensing agreements with Ionis. The company's involvement in the manufacturing and marketing of Olezarsen sodium is significant as it consolidates supply infrastructure in various global markets.

Supply Role:
Novartis operates advanced manufacturing facilities to produce the API or formulated products at scale. The company has invested heavily in oligonucleotide manufacturing platforms, including specialized synthesis, purification, and formulation units.

Manufacturing Capabilities:
With multiple GMP-certified plants globally, Novartis ensures high-volume, quality-controlled API production, enabling swift scaling to meet market demand.

3. Commercial-Scale CMOs and Contract Development Manufacturers

a. WuXi AppTec

Overview:
WuXi AppTec, a leading CMO specializing in small molecule and biological manufacturing, is known for contract synthesis of oligonucleotide APIs, including oligonucleotides similar to Olezarsen sodium.

Supply Role:
WuXi offers custom oligonucleotide API manufacturing, filling capacity gaps in cases of high demand or manufacturing bottlenecks. Their facilities are GMP-compliant, with a focus on scalable production.

b. Cambrex Corporation

Overview:
Cambrex, a global provider of APIs and intermediates, has expanded into oligonucleotide synthesis, offering manufacturing services tailored for nucleic acid-based therapies.

Supply Role:
While not the primary manufacturer of Olezarsen sodium, Cambrex's capacity to produce oligonucleotide APIs makes it a potential supplier or backup source.

c. BioSpring GmbH

Overview:
Specializing in complex oligonucleotide synthesis and manufacturing for clinical and commercial use, BioSpring caters to pharmaceutical clients involved in nucleic acid therapeutics.

Supply Role:
BioSpring could be a strategic partner or alternative supplier for custom synthesis or scale-up phases.

Formulation and Finished Product Manufacturing

European and US-based Contract Manufacturers: Several firms focus on the formulation of oligonucleotide-based drugs, adding critical components such as stabilizers, excipients, and delivery systems.
Packaging & Distribution: The final product distribution relies on established pharmaceutical wholesalers and logistics providers compliant with temperature-controlled supply chains.

Distribution Channels and Market Access

Global Distribution: Key markets include North America, Europe, and Asia-Pacific. Major distributors act as intermediaries for pharmacy chains, hospitals, and specialty clinics.
Regulatory Approvals: Ensuring supply chain integrity, manufacturers and suppliers must align with regulatory agencies such as the FDA (US), EMA (Europe), and other regional bodies.

Market Dynamics and Supply Chain Challenges

Complexity of Oligonucleotide Synthesis: Custom synthesis and purification processes necessitate specialized facilities, limiting the number of qualified suppliers.
Patent and Licensing Frameworks: Patent protections and licensing agreements, especially involving Ionis and Novartis, influence manufacturing rights and access.
Supply Chain Risks: Disruptions in raw material availability, geopolitical factors, and stringent regulatory requirements pose challenges to consistent supply.
Emerging Competitors: Efforts by biotech startups and contract manufacturing firms to develop proprietary oligonucleotide synthesis capabilities could diversify future supplier landscapes.

Strategic Implications for Stakeholders

Pharmaceutical Companies: Establishing diversified supplier relationships mitigates risks associated with reliance on a single source.
Investors and Market Analysts: Monitoring contractual partnerships, expansions in manufacturing capacity, and regulatory approvals inform supply expectations and market penetration.
Healthcare Providers: Access to reliable supply directly impacts patient treatment availability, emphasizing the importance of supply chain resilience.

Key Takeaways

Leading Developer: Ionis Pharmaceuticals holds a foundational role in the production of Olezarsen sodium, often through licensing agreements with large pharma firms.
Major Commercial Partners: Novartis, leveraging advanced GMP manufacturing platforms, is a key player in scaling supply for commercial distribution.
Contract Manufacturers: Facilities like WuXi AppTec and BioSpring provide essential capacity for oligonucleotide synthesis but are typically engaged under specific contractual arrangements.
Supply Chain Complexity: The specialized nature of oligonucleotide manufacturing, patent protections, and regional regulatory requirements complicate supply chain dynamics, requiring strategic management.
Future Outlook: Increasing demand and technological innovations, such as automated synthesis and purification, will likely expand the pool of qualified suppliers, enhancing supply stability.

FAQs

1. Who are the primary suppliers responsible for manufacturing Olezarsen sodium's API?
Ionis Pharmaceuticals is the original developer and maintains significant manufacturing capabilities. Partnered or licensed firms like Novartis frequently produce or oversee the production of the API at a commercial scale. Several CMO firms, including WuXi AppTec and BioSpring, are equipped to provide custom oligonucleotide synthesis services, making them potential secondary suppliers.

2. How does supplier complexity impact the delivery of Olezarsen sodium?
The intricate synthesis process of oligonucleotides, combined with strict regulatory compliance, limits the number of qualified suppliers. This complexity can lead to supply chain bottlenecks, necessitating diversified sourcing strategies to ensure steady availability and mitigate risks.

3. Are there regional differences in Olezarsen sodium suppliers?
Yes. The US and Europe predominantly host manufacturing facilities operated by Ionis, Novartis, and specialized CMOs. In Asia-Pacific, including China and India, emerging local suppliers are developing capabilities, though the market remains concentrated among established firms due to technical challenges.

4. What factors influence the choice of suppliers for pharmaceutical companies?
Regulatory compliance, manufacturing capacity, quality assurance, cost efficiency, and intellectual property considerations primarily influence sourcing decisions. Strategic alliances with established firms like Ionis or Novartis provide security of supply and regulatory support.

5. Will technological advances alter the supplier landscape for oligonucleotide drugs?
Yes. Innovations in automated synthesis, purification, and scalable manufacturing are reducing barriers, potentially increasing the number of capable suppliers. This evolution will foster greater competition, pricing advantages, and supply resilience.

References

Note: Data is based on publicly available sources, industry reports, and market analysis as of early 2023.

Suppliers and packagers for generic pharmaceutical drug: olezarsen sodium